Toggle light / dark theme

Being able to see, move, and exercise independently is something most of us take for granted. [Thomas Panek] was an avid runner before losing his sight due to a genetic condition, and had to rely on other humans and guide dogs to run again. After challenging attendants at a Google hackathon, Project Guideline was established to give blind runners (or walkers) independence from a cane, dog or another human, while exercising outdoors. Using a smartphone with line following AI software, and bone conduction headphones, users can be guided along a path with a line painted on it. You need to watch the video below to get a taste of just how incredible it is for the users.

Getting a wheeled robot to follow a line is relatively simple, but a running human is by no means a stable sensor platform. At the previously mentioned hackathon, developers put together a rough proof of concept with a smartphone, using its camera to recognize a painted line on the ground and provide left/right audio cues. As the project developed, the smartphone was attached to a waist belt and bone conduction headphones were used, which don’t affect audio situational awareness as much as normal headphones.

The shaking and side to side movement of running, and varying light conditions and visual obstructions in the outdoors made the problem more difficult to solve, but within a year the developers had completed successful running tests with [Thomas] on a well-lit indoor track and an outdoor pedestrian path with a temporary line. For the first time in 25 years, [Thomas] was able to run independently.

Andres de Tenyi.


Yuri Deigin, MBA is a serial biotech entrepreneur, longevity research evangelist and activist, and a cryonics advocate. He is an expert in drug development and venture investments in biotechnology and pharmaceuticals. He is the CEO at Youthereum Genetics and the Vice President at Science for Life Extension Research Support Foundation.
http://youthereum.ca/

Yuri has a track record of not only raising over $20 million for his previous ventures but also initiating and overseeing 4 clinical trials and several preclinical studies, including studies in transgenic mice.

At Youthereum Genetics, Yuri is currently leading a project dedicated to developing an epigenetic rejuvenation gene therapy, as intermittent epigenetic partial reprogramming demonstrated great experimental results in mice: it extended their lifespan by up to 50%.

His life goal is to do everything possible to minimize human suffering from various diseases, especially terminal age-related diseases such as cancer, Alzheimer’s, and cardiovascular disease and to help humanity eradicate them. As an activist, blogger, and speaker, he is conveying the magnitude of human suffering these diseases cause, as they take over 100,000 lives each day. As a biotech entrepreneur, Yuri is doing his modest part by putting together projects that could yield such therapies, splitting his time between Toronto and Moscow.

He believes that one day humanity will cure all such diseases, and he wants to do whatever he can to hasten that day.

Since 2013, Yuri also serves as the Vice President of the nonprofit Foundation, Science for Life Extension, whose goal is the popularization of the fight against age-related diseases. To further this cause, Yuri frequently blogs, speaks, writes op-ed pieces, and participates in various TV and radio shows. At the Science for Life Extension Foundation, Yuri is helping the Foundation create and implement social change strategies to create public awareness that aging is a curable disease. He is also working on initiating intergovernmental dialog and public hearings about including aging in WHO’s ICD-11.

Previously, Yuri was the COO and Managing Director at Pharma Bio in Moscow for almost 7 years. From 2015 to 2017, Yuri was the Vice President of Business Development at Manus Pharmaceuticals in Toronto, Canada where he worked on raising funding and forming strategic partnerships to develop breakthrough peptide compounds aimed at preventing Alzheimer’s disease. Before that, he was the VP of Business Development at Peptos Pharma in Moscow.

Takeaways * Scientists have made progress growing human liver in the lab. * The challenge has been to direct stems cells to grow into a mature, functioning adult organ. * This study shows that stem cells can be programmed, using genetic engineering, to grow from immature cells into mature tissue. * When a tiny lab-grown liver was transplanted into mice with liver disease, it extended the lives of the sick animals.* * *Imagine if researchers could program stem cells, which have the potential to grow into all cell types in the body, so that they could generate an entire human organ. This would allow scientists to manufacture tissues for testing drugs and reduce the demand for transplant organs by having new ones grown directly from a patient’s cells. I’m a researcher working in this new field – called synthetic biology – focused on creating new biological parts and redesigning existing biological systems. In a new paper, my colleagues and I showed progress in one of the key challenges with lab-grown organs – figuring out the genes necessary to produce the variety of mature cells needed to construct a functioning liver. Induced pluripotent stem cells, a subgroup of stem cells, are capable of producing cells that can build entire organs in the human body. But they can do this job only if they receive the right quantity of growth signals at the right time from their environment. If this happens, they eventually give rise to different cell types that can assemble and mature in the form of human organs and tissues. The tissues researchers generate from pluripotent stem cells can provide a unique source for personalized medicine from transplantation to novel drug discovery. But unfortunately, synthetic tissues from stem cells are not always suitable for transplant or drug testing because they contain unwanted cells from other tissues, or lack the tissue maturity and a complete network of blood vessels necessary for bringing oxygen and nutrients needed to nurture an organ. That is why having a framework to assess whether these lab-grown cells and tissues are doing their job, and how to make them more like human organs, is critical. Inspired by this challenge, I was determined to establish a synthetic biology method to read and write, or program, tissue development. I am trying to do this using the genetic language of stem cells, similar to what is used by nature to form human organs. Tissues and organs made by genetic designsI am a researcher specializing in synthetic biology and biological engineering at the Pittsburgh Liver Research Center and McGowan Institute for Regenerative Medicine, where the goals are to use engineering approaches to analyze and build novel biological systems and solve human health problems. My lab combines synthetic biology and regenerative medicine in a new field that strives to replace, regrow or repair diseased organs or tissues. I chose to focus on growing new human livers because this organ is vital for controlling most levels of chemicals – like proteins or sugar – in the blood. The liver also breaks down harmful chemicals and metabolizes many drugs in our body. But the liver tissue is also vulnerable and can be damaged and destroyed by many diseases, such as hepatitis or fatty liver disease. There is a shortage of donor organs, which limits liver transplantation. To make synthetic organs and tissues, scientists need to be able to control stem cells so that they can form into different types of cells, such as liver cells and blood vessel cells. The goal is to mature these stem cells into miniorgans, or organoids, containing blood vessels and the correct adult cell types that would be found in a natural organ. One way to orchestrate maturation of synthetic tissues is to determine the list of genes needed to induce a group of stem cells to grow, mature and evolve into a complete and functioning organ. To derive this list I worked with Patrick Cahan and Samira Kiani to first use computational analysis to identify genes involved in transforming a group of stem cells into a mature functioning liver. Then our team led by two of my students – Jeremy Velazquez and Ryan LeGraw – used genetic engineering to alter specific genes we had identified and used them to help build and mature human liver tissues from stem cells. The tissue is grown from a layer of genetically engineered stem cells in a petri dish. The function of genetic programs together with nutrients is to orchestrate formation of liver organoids over the course of 15 to 17 days. Liver in a dishI and my colleagues first compared the active genes in fetal liver organoids we had grown in the lab with those in adult human livers using a computational analysis to get a list of genes needed for driving fetal liver organoids to mature into adult organs. We then used genetic engineering to tweak genes – and the resulting proteins – that the stem cells needed to mature further toward an adult liver. In the course of about 17 days we generated tiny – several millimeters in width – but more mature liver tissues with a range of cells typically found in livers in the third trimester of human pregnancies. Like a mature human liver, these synthetic livers were able to store, synthesize and metabolize nutrients. Though our lab-grown livers were small, we are hopeful that we can scale them up in the future. While they share many similar features with adult livers, they aren’t perfect and our team still has work to do. For example, we still need to improve the capacity of the liver tissue to metabolize a variety of drugs. We also need to make it safer and more efficacious for eventual application in humans.[Deep knowledge, daily. Sign up for The Conversation’s newsletter.]Our study demonstrates the ability of these lab livers to mature and develop a functional network of blood vessels in just two and a half weeks. We believe this approach can pave the path for the manufacture of other organs with vasculature via genetic programming. The liver organoids provide several key features of an adult human liver such as production of key blood proteins and regulation of bile – a chemical important for digestion of food. When we implanted the lab-grown liver tissues into mice suffering from liver disease, it increased the life span. We named our organoids “designer organoids,” as they are generated via a genetic design. This article is republished from The Conversation, a nonprofit news site dedicated to sharing ideas from academic experts. It was written by: Mo Ebrahimkhani, University of Pittsburgh. Read more: * Brain organoids help neuroscientists understand brain development, but aren’t perfect matches for real brains * Why are scientists trying to manufacture organs in space?Mo Ebrahimkhani receives funding from National Institute of Health, University of Pittsburgh and Arizona Biomedical Research Council.

Coronaviruses are enveloped, positive-stranded RNA viruses with a genome of approximately 30 kb. Based on genetic similarities, coronaviruses are classified into three groups. Two group 2 coronaviruses, human coronavirus OC43 (HCoV-OC43) and bovine coronavirus (BCoV), show remarkable antigenic and genetic similarities. In this study, we report the first complete genome sequence (30,738 nucleotides) of the prototype HCoV-OC43 strain (ATCC VR759). Complete genome and open reading frame (ORF) analyses were performed in comparison to the BCoV genome. In the region between the spike and membrane protein genes, a 290-nucleotide deletion is present, corresponding to the absence of BCoV ORFs ns4.9 and ns4.8. Nucleotide and amino acid similarity percentages were determined for the major HCoV-OC43 ORFs and for those of other group 2 coronaviruses. The highest degree of similarity is demonstrated between HCoV-OC43 and BCoV in all ORFs with the exception of the E gene. Molecular clock analysis of the spike gene sequences of BCoV and HCoV-OC43 suggests a relatively recent zoonotic transmission event and dates their most recent common ancestor to around 1890. An evolutionary rate in the order of 4 × 10−4 nucleotide changes per site per year was estimated. This is the first animal-human zoonotic pair of coronaviruses that can be analyzed in order to gain insights into the processes of adaptation of a nonhuman coronavirus to a human host, which is important for understanding the interspecies transmission events that led to the origin of the severe acute respiratory syndrome outbreak.

Coronaviruses are large (120- to 160-nm), roughly spherical particles with a linear, nonsegmented, capped, and polyadenylated positive-sense single-stranded RNA genome that is encapsidated in a helical nucleocapsid. The envelope is derived from intracellular membranes and contains a characteristic crown of widely spaced club-shaped spikes that are 12 to 24 nm long. The genus Coronavirus (International Committee on the Taxonomy of Viruses database [ICTVdb], virus code 03.019.0.1) belongs to the family Coronaviridae in the order Nidovirales (7, 8).

Before the 2002-to-2003 severe acute respiratory syndrome (SARS) epidemic, coronaviruses were somewhat neglected in human medicine, but they have always been of considerable importance in animal health. Coronaviruses infect a variety of livestock, poultry, and companion animals, in whom they can cause serious and often fatal respiratory, enteric, cardiovascular, and neurologic diseases (25). Most of our understanding about the molecular pathogenic properties of coronaviruses has been achieved by the veterinary virology community.

I didn’t realize there were so many 3rd-party genetic analysis services. If you’ve already done something like 23andMe have you tried uploading your raw DNA data to one of these other websites?


Note: This piece on genetic analysis is the third in our series of posts about DNA tests for health and longevity. To better understand the basics of DNA and the different types of DNA tests on the market please go back and read our first piece on The Benefits of Genetic Testing for Longevity, and for an in-depth comparison of DNA testing companies please read the second piece on the Best DNA Tests for Health and Longevity.

Affiliate Disclaimer: Longevity Advice is reader-supported. When you buy using links on our site, we may earn commissions.

Imagine, for a moment, that time travel is real.

Imagine swabbing your nostrils, putting the swab in a device, and getting a read-out on your phone in 15 to 30 minutes that tells you if you are infected with the COVID-19 virus. This has been the vision for a team of scientists at Gladstone Institutes, University of California, Berkeley (UC Berkeley), and University of California, San Francisco (UCSF). And now, they report a scientific breakthrough that brings them closer to making this vision a reality.

One of the major hurdles to combating the COVID-19 pandemic and fully reopening communities across the country is the availability of mass rapid testing. Knowing who is infected would provide valuable insights about the potential spread and threat of the virus for policymakers and citizens alike.

Yet, people must often wait several days for their results, or even longer when there is a backlog in processing lab tests. And, the situation is worsened by the fact that most infected people have mild or no symptoms, yet still carry and spread the virus.

Exploring the frontiers of neuromodulation, neurostimulation, and neural interfaces.


Neuromodulation is defined as “the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body”. It is carried out to normalize – or modulate – nervous tissue function.

Neuromodulation is an evolving therapy that can involve a range of electromagnetic stimuli such as a magnetic field, an electric current, or a drug instilled directly in the sub-dural space (i.e. intra-thecal drug delivery).

Emerging applications involve targeted introduction of genes or gene regulators and light (optogenetics), but most clinical experience has been with electrical stimulation.

Existing and emerging neuromodulation treatments also include application in medication-resistant epilepsy, chronic head pain conditions, and functional therapy ranging from bladder and bowel or respiratory control, to improvement of sensory deficits, such as hearing and vision.

Neuromodulation therapy has been investigated for other chronic conditions, such as Alzheimer’s disease, depression, chronic pain, and as an adjunctive treatment in recovery from stroke.

Dr. Amílcar dos Santos, is a practicing Psychiatrist at the Psychiatry Service of Hospital Vila Franca de Xira, in Lisbon, Portugal, with expertise in Neuromodulation / Neurostimulation, Hospitalization of acute patients, Psychiatric Emergency Service, Outpatient Psychiatry, Electroconvulsive therapy (ECT), and Psychoeducation for Bipolar Disease.

Dr. dos Santos has a Degree in Medicine from the Faculty of Medicine of the University of Lisbon (FMUL) and Post-Graduate in Neuroscience at FMUL.

Scientists have recovered DNA from a well-preserved horned lark found in Siberian permafrost. The results can contribute to explaining the evolution of sub species, as well as how the mammoth steppe transformed into tundra, forest and steppe biomes at the end of the last Ice Age.

In 2018, a well-preserved frozen bird was found in the ground in the Belaya Gora area of north-eastern Siberia. Researchers at the Centre for Palaeogenetics, a new research center at Stockholm University and the Swedish Museum of Natural History, haves studied the bird and the results are now published in the scientific journal Communications Biology. The analyses reveals that the bird is a 46,000-year-old female horned lark.

“Not only can we identify the bird as a horned lark. The genetic analysis also suggests that the bird belonged to a population that was a joint ancestor of two sub species of horned lark living today, one in Siberia, and one in the steppe in Mongolia. This helps us understand how the diversity of sub species evolves,” says Nicolas Dussex, researcher at the Department of Zoology at Stockholm University.